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CD8 T cells play a vital role in the immunological protection against intracellular pathogens. Ideally, robust eﬀector responses
are induced, which eradicate the pathogen, and durable memory CD8 T cells are also established, which help confer protection
against subsequent reinfection. The quality and magnitude of these responses is dictated by multiple factors, including their
initial interactions with professional antigen-presenting cells, as well as the cytokine milieu and availability of CD4 T cell help.
These factors set the transcriptional landscape of the responding T cells, which in turn inﬂuences their phenotypic and functional
attributes as well as ultimate fate. Under certain conditions, such as during chronic infections, the development of these usually
successfulresponsesbecomessubverted.Herewediscussadvancesinourunderstandingofthecellularandmoleculardeterminants
of T cell quality, and the formation of eﬀector, memory, and exhausted CD8 T cells, during acute and chronic infections.
1.Introduction
The induction of CD4 and CD8 T cell responses, in con-
junction with innate immunity and antibodies, helps protect
against pathogens including viruses, bacteria, fungi, and
eukaryoticparasites.CD8Tcellsareofparticularimportance
in mediating elimination of intracellular pathogens due to
their ability to recognize and kill infected cells. Current vac-
cination strategies are aimed at eliciting B cell responses and
conferring antibody-mediated protection; however interest
has been steadily growing in the development of vaccines
designed to prime durable memory T cells [1–5]. T cell-
based protective approaches may be particularly advanta-
geous in helping protect against or in controlling chronic
infections such as hepatitis B virus (HBV), hepatitis C virus
(HCV), and human immunodeﬁciency virus (HIV).
A better understanding of the factors that yield strong
primary and memory T cell responses is likely to beneﬁt
the development of both T cell-based vaccines and new
therapeutic options for chronic infections as well as tumors.
Critical issues that are at best only partially understood
include deﬁning the variables which regulate the induc-
tion and maintenance of long-lived memory responses;
decipheringthedistinguishingfeaturesofprotectiveimmune
responses, including the molecular and cellular traits of
“successful” T cell responses; and determining how these
responses integrate with other immune system components
and act in concert to confer immunological protection.
Analyses of immune responses to infections in both animal
model systems and in clinical studies using human samples
are helping to unravel these complex issues.
2.FunctionalQualityof CD8TCell Responses
duringAcute and ChronicInfections
The functionality of CD8 T cells is shaped at each stage
of the immune response by multiple factors, including the
duration and strength of antigenic stimulation, interactions
between T cells and antigen presenting cells (APCs), the
inﬂammatory milieu, costimulatory requirements, cytokine
and chemokine availability, and the presence of CD4 T cell
help. These factors inﬂuence the expression of transcription
factors that regulate the diﬀerentiation and phenotypic
properties of CD8 T cells and collectively function to dictate2 Journal of Biomedicine and Biotechnology
the development of eﬀector T cells and the establishment of
the memory pool.
Manyacuteinfectionselicitmassiveantigen-speciﬁcCD8
T cell responses which contribute to the successful clearance
ofthepathogen[6–15].Theoverallpoolofexpandedeﬀector
cells, induced during the initial phase of the response, is
heterogeneous and comprised of subsets which diﬀer in their
epitope-speciﬁcity, clonal abundance, anatomical location,
eﬀector potential, expression of surface markers, and fate.
Typically only a fraction (5%–10%) of this expanded ensem-
ble of antigen-speciﬁc CD8 T cells survives the subsequent
downregulation of the response and proceeds to constitute
the long-lived memory pool (Figure 1(a)). Thus, following
the clearance of the infection, an increased number of
antigen-speciﬁc T cells are now present which are tuned
to rapidly respond if they reencounter infected cells [16–
21]. Taken together, this highlights two points regarding the
development of long-lived, protective, CD8 T cell memory.
First, the ideal primary response not only eradicates the
infection but also generates a set of “precursors” which
can form the memory pool. Second, once the infection is
controlled,itiscriticaltomaintainboththephysicalpresence
as well as the functional potential of these memory cells in
order to confer T cell-mediated immunological protection.
Memory T cell populations are remarkably heteroge-
neous and diﬀer in many ways including their capacity to
execute eﬀector functions, their ability to proliferate upon
secondary challenge, and also their anatomical location.
Based on these traits, memory T cell populations have been
broadly segregated into “eﬀector-memory” and “central-
memory” subsets. Eﬀector-memory T cells express low levels
of CD62L and CCR7 and generally exhibit a high degree of
eﬀector activity, low proliferative capacity, and preferentially
reside in tissues where they can serve as sentinels to protect
against localized infections. By contrast, central-memory T
cells generally express high levels of CCR7 and CD62L,
have a higher proliferative capacity, and reside in secondary
lymphoid organs [22–24]. The lineage relationships between
these two subsets, and what factors endow speciﬁc functions
upon these populations, are an area of debate within the ﬁeld
[24–26].
Although CD8 T cells can be highly eﬀective at control-
ling acute infections and contribute to protective secondary
responses, protracted and chronic infections do arise and are
often associated with the development of phenotypically and
functionally inferior responses [14, 27–46]. These types of
infections include many pathogens which are of signiﬁcant
global public health importance, such as HIV and HCV. A
common feature of more protracted and chronic infections
is that antiviral CD8 T cells are initially triggered, but
qualitative and quantitative defects become apparent in
the generation of robust sets of eﬀector cells as well as
the progression of memory T cell development. T cell
responses generated under these conditions are susceptible
to exhaustion, which is characterized by the stepwise and
progressive loss of eﬀector functions. Consequently, these
responses are incapable of clearing the pathogen. The
ability to produce the cytokine IL-2 and undergo robust
proliferation appears to be highly sensitive to exhaustion
and are the ﬁrst functional qualities lost by CD8 T cells
during protracted and chronic infections [29, 39, 41]. TNFα
production and IFNγ production are more robust functions;
however, even these abilities are lost at more severe stages
of exhaustion, and T cells speciﬁc for certain epitopes may
even be deleted [29, 39, 41, 47, 48]( Figure 1). Ex vivo
killing activities are diﬃcult to detect by exhausted cells;
however, in vivo killing has been documented [29, 49].
Thus, these cells may retain some residual cytotoxic activity
within the persistently infected host, although the biological
signiﬁcance of this killing activity is unclear given the failure
to contain the infection.
Despite the functional ineptness of exhausted CD8 T
cells, they express patterns of surface receptors which are
commonly associated with activated eﬀector T cells. They
express high levels of CD69 and CD43 (1B11) but low levels
ofCD62LandCD127[29,30,42,45,48,50].ExhaustedCD8
T cells also express constellations of inhibitory receptors,
most notably PD-1 [43, 51–53], but also LAG-3 and high
levels of CD244 [54]. Varying levels of exhausted and
defective CD8 T cell responses have been observed following
many infections, including lymphocytic choriomeningitis
virus (LCMV) [28, 29, 31, 47, 48, 55], polyoma virus [56],
adenovirus [57], Friend leukemia virus [58–60], mouse
hepatitis virus [61], HIV [34, 51, 62–64], HBV [65, 66],
and HCV [33, 36, 52, 66, 67], and have also been observed
in patients with malignancies [68–71]. As further discussed
below, the development of the exhausted state is generally
more severe if CD4 T cell help is inadequate.
3.PrimingCD8TCellResponses by
Professional Antigen-Presenting Cells
Na¨ ıve CD8 T cells become activated when they encounter
professional antigen-presenting cells (APC) displaying cog-
nate peptide antigen complexed with an appropriate MHC
class I molecule. The ability of CD8 T cells to survey these
MHC-peptide complexes allows these cells to fulﬁll their
immunological surveillance functions and is the essential
ﬁrst step for launching the CD8 T cell response. The
interaction between the na¨ ıve CD8 T cell and the APC allows
the antigen-speciﬁc cells to receive TCR signals (signal 1) as
well as costimulation (signal 2) [72]( Figure 2). These signals
are conveyed as the T cell and APC form an immunological
synapse (IS) consisting of TCR/MHC-peptide complexes
and CD28/CD80-CD86 interactions, which provide signals
1 and 2, respectively, to the responding T cell. As the
cells couple, these signaling molecules colocalize within
the plasma membrane forming a central supramolecular
activation cluster (cSMAC), while adhesion molecules such
as lymphocyte function-associated antigen- (LFA-) 1 and
intracellular adhesion molecule- (ICAM-) 1 surround the
cSMAC, forming the peripheral supramolecular activation
cluster(pSMAC)[73,74].LFA-1/ICAM-1interactionsmedi-
ate long duration contact between the T cell and the APC
[75, 76], and it has been shown that ICAM-1 deﬁciency on
the APC impedes long duration contact formation [76].Journal of Biomedicine and Biotechnology 3
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(a) Rapidly controlled pathogen (acute)
e e
e
e
e
e
2
2 e
e e
e
e
e
e
e e 2 e
e
e
e
e
e e e
e
e
e
e
e
e
e
e
e
e e
e
e
e
e
2
γ
γ
γ
γ γ
γ
e e e e
e e
e e
e e
e e
2 2
2 2 γ
γ
γ
γ
γ
γ
γ
γ
γ
γ
γ
γ
γ
γ
γ
γ
γ γ
γ
γ
α
α γ e e
e e e e
e e
γ γ e e
e e
e e
e e e e 2 2 γ
γ
γ
γ γ α
e e
γ
γ
α
α α
e e
e e
e e
e e α
α α e e e e e e
e e
e e
γ
γ
γ γ
e e
e e γ
e e
e e
e e
e e
e e
e e e e
e e
e e
e e
e e
2 2
Time after infection
N
u
m
b
e
r
o
f
p
a
t
h
o
g
e
n
-
s
p
e
c
i
ﬁ
c
C
D
8
T
c
e
l
l
s
(b) Slowly controlled pathogen (protracted)
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(c) Pathogen never controlled (chronic)
Figure 1: Pathogen-speciﬁc T cell responses to acute and chronic
infections vary in magnitude and functional attributes. (a) Acute
infections elicit a large CD8 T cell response, and after resolution
of the infection the memory pool is typically composed of
polyfunctional T cells capable of coproducing IFNγ,T N F α, and IL-
2( g r e e nc i r c l e s )o rI F N γ and TNFα (blue circles). (b) Protracted
infections are associated with weaker responses and reductions
in the functional quality of the responding T cells, such as the
emergence of CD8 T cells which only produce IFNγ (red circles)
as well as the development of exhausted cells that are functionally
incapacitated (black circles). The overall quality of the response
may improve as the infection is brought under control. (c) High-
grade viral persistence during chronic infection results in severe
functional exhaustion and the possible deletion of antigen-speciﬁc
CD8 T cells.
Stable formation of the IS allows strong signaling to
the responding CD8 T cell and also keeps the cell in close
proximity to the priming APC. This allows the CD8 T
cell to receive “signal 3” in the form of cytokines such
as IL-12 and other inﬂammatory mediators, which also
inﬂuencethefunctionalattributesofthedevelopingresponse
[77–83]. Signaling via IL-12 supports the proliferation and
development of cytolytic activity in CD8 T cells in vitro
[77, 79, 84] and can act as an adjuvant during peptide
immunization in vivo [78, 80–82]. This ability to promote
eﬀector CD8 T cell responses is further shown by ﬁndings
that IL-12 can drive the formation of eﬀector CD8 T cells,
which are distinguished by their expression of high levels
of KLRG-1 and low levels of CD127 [82, 83]. The primary
producers of IL-12 are dendritic cells, macrophages, and
monocytes, which produce the cytokine in response to
inﬂammatory signals including IFNγ. These two cytokines
act in a positive feedback loop in which IFNγ activates
the APC to produce IL-12, and then IL-12 induces more
IFNγ production by the CD8 T cell [85, 86]. In addition to
promotingIFNγ production,IL-12andIFNαhavebothbeen
shown to enhance induction of other eﬀector molecules,
such as granzyme B and Fas ligand, when combined with
TCR ligation and costimulation [77, 84].
4.CD4TCellHelpfor CD8TCells
CD4 T cells contribute to immunological protection against
both intracellular and extracellular pathogens. These cells
have multifaceted roles and function to help B and T cell
responses by promoting the activation of professional APCs
via interactions with costimulatory molecules and by the
secretion of cytokines and chemokines. During typical viral
infections, CD4 T cells are primarily polarized to the Th1
lineage and produce the cytokines IFNγ,T N F α,a n dI L - 2
[8, 87, 88]. The more recently described T follicular helper
(Tfh) subset of CD4 T cells, which promote germinal center
formation, are also generated following infection [89, 90].
TheimportanceofCD4TcellsinhelpingCD8Tcellshas
become increasingly well described [29, 30, 39, 48, 91–105].
Although deceptively potent primary CD8 T cell responses
can be induced in the absence of CD4 T cells, the subsequent
establishment of long-lived, functionally robust memory
CD8 T cells is compromised [29, 30, 91–102, 106–109].
CD8 T cell responses elaborated in the absence of CD4 T
cell help may remain in an eﬀector-like state, associated
with the constitutive expression of the transcription factor
T-bet, but develop a spectrum of functional defects which
increase in severity with time [29, 30, 48, 97, 101, 110].
Prototypic memory CD8 T cells primed and maintained in
the presence of CD4 T cell help are typically CD62Llo/hi,
CD122hi, and CD127hi whereas their helpless counterparts
are predominantly CD62Llo, CD122lo, and CD127lo and may
not be stably maintained [30, 91, 97]. Additionally, marked
reductions in the capacity to produce cytokines, especially
IL-2, as well as diminished secondary proliferative responses
are hallmarks of inadequately helped memory CD8 T cells
[30, 91, 92, 95–97, 99–101].4 Journal of Biomedicine and Biotechnology
It has been proposed that CD4 T cells operate to
“program” the development of robust, long-lived memory
CD8 T cells [95, 96]. This model suggests that as na¨ ıve CD8
T cells respond to antigenic stimulation, CD4 T cells imprint
the subsequent development of memory traits. Accordingly,
if CD4 T cell help is not applied, the responding CD8 T cells
aremisprogrammedandareincapableoffullydiﬀerentiating
into authentic memory T cells. An alternative maintenance
model has also been put forward to account for the helper
dependency of memory CD8 T cell responses [93, 101].
This model suggests that CD4 T cells are not required for
the initial programming of memory precursors during the
priming phase but are instead required for their subsequent
survival and the maintenance of functional potential. Which
of these models best accounts for defective CD8 T cell
memory in helpless hosts is not resolved. It is plausible that
the requirement for CD4 T cell help is biphasic and that
the presence of CD4 T cells during the induction phase may
enhance the generation or “programming” of CD8 T cells
whichmatureintomemoryCD8Tcells,andthatCD4Tcells
also subsequently operate to sustain the functional potential
and numbers of these cells over time.
CD4 T cells are thought to deliver their help to CD8 T
cellsinseveralways.CD4Tcells“license”antigen-presenting
cells via CD40-CD40L interactions, empowering them to
launch CD8 T cell responses [111–114]( Figure 2). It has also
been proposed that the APC requirement can be bypassed,
requiring direct delivery of the helper signal from the CD4 T
cell to the CD8 T cell [115]. CD4 T cells not only play a role
in activating dendritic cells but also produce the chemokines
CCL3 and CCL4, which promote the migration of CD8 T
cells toward these activated dendritic cells [116, 117]. Later
in the response, CD4 T cells can stimulate the traﬃcking of
CD8 T cells to sites of infection by the secretion of IFNγ as
well as the chemokines CXCL9 and CXCL10 [118].
Cytokine production is a cardinal trait of activated
CD4 T cells and two related cytokines, IL-2 and IL-21,
produced by these cells have been shown to impact gene
regulation, function, and fate of responding CD8 T cells
(Figure 2). IL-2 provides growth and diﬀerentiation signals
torespondingCD8Tcells[119–121],andIL-2signalsduring
priming are required for CD8 T cells to be subsequently
capable of expanding upon rechallenge [122, 123]. Both
IL-2 signaling and IL-21 signaling drive the upregulation
of B lymphocyte-induced maturation protein 1 (Blimp-1/
Prdm1), a transcription factor known to induce CD8 T
cell diﬀerentiation and eﬀector function (discussed further
below) [124–126]. CD8 T cells are also able to produce IL-
2 upon TCR ligation [127–129]; however after the initial
activation the responding T cells enter a period termed
“activation-induced nonresponsiveness” (AINR) [130–133].
During this time T cells are still able to lyse target cells and
produce IFNγ but are dependant on paracrine IL-2 supplied
by CD4 T cells for further proliferation. After receiving these
CD4 derived IL-2 signals, the responding CD8 T cells are
rewired to allow IL-2 mRNA upregulation and proliferation
in response to TCR signals in the absence of costimulation
[132]. CD8 T cells primed in the absence of CD4 T cells are
defective at mounting recall responses [92, 96, 97, 99, 100],
CD4
APC CD8
3 IL-12
IL-2, IL-21
1
2
Figure 2: Successful activation of CD8 T cells requires three signals
by APCs and CD4 T cell help. CD8 T cells engage cognate peptide-
MHC complexes presented on APCs with their TCR (1). The
APC also provides costimulation to the T cell via expression of
CD80/CD86 molecules, which bind to CD28 on the T cell (2).
Finally, the APC produces IL-12 after activation with inﬂammatory
mediators or in response to CD40L interactions with CD4 T cells,
andIL-12providessignal3totherespondingCD8Tcell.(3)CD4T
cells also produce cytokines that provide growth and diﬀerentiation
signals to responding CD8 T cells.
and this defect mirrors what is observed if IL-2 signals are
not available during priming [122, 123]. Accordingly, these
ﬁndings support a model by which IL-2 production by CD4
T cells legitimizes the response and allows the CD8 T cells to
become full-ﬂedged memory cells.
IL-21 is a 15kDa member of the common γ-chain
cytokine family and is most closely related to IL-2, which is
encoded directly upstream of IL-21 on chromosomes 3 and
4, in mice and humans, respectively [134]. IL-21 is primarily
produced by CD4 T cells and has been implicated in helping
CD8 T cells [135, 136]. IL-21 binds to a heterodimeric
receptor comprised of the common-γ chain (CD132) and
the unique IL-21 receptor, encoded on chromosome 7 and
16, in mice and humans, respectively [137]. The IL-21
receptor is widely distributed and is expressed by B cells, NK
cells, dendritic cells, macrophages, keratinocytes, and CD4+
and CD8+ T cells [134, 137]. Overexpression of IL-21 in
mice results in expansion of CD8 T cells with a memory
p h e n o t yp ea tt h ee x p e n s eo fn a ¨ ıve CD8 T cells [138]. In vitro
studies of T cell priming have shown that IL-21 can function
as a “third” signal, acting in concert with TCR ligation and
costimulation, to drive proliferation of na¨ ıve CD8 T cells
andthedevelopmentofcytolyticactivity[139].Thesestudies
both suggest a role for IL-21 in expanding responding CD8
T cell populations.
In the absence of CD4 T cell help, defects in the CD8 T
cell responses manifest following acute infections; however,
these impairments are even more severe during persistent
infections. Several groups have recently demonstrated a
critical role for IL-21 in helping CD8 T cell responses during
chronicinfections[140–143].BothIL-21andIL-21receptor-
deﬁcient mice develop a chronic infection following inocu-
lation with certain strains of LCMV, an outcome identical
to that observed in CD4 deﬁcient mice [140–142]. Using a
series of mixed bone marrow chimeras, IL-21 was shown to
act directly on CD8 T cells to support these responses during
chronic infections. CD8 T cells that could not receive IL-
21 signals exhibited exacerbated functional exhaustion and
were rapidly deleted when in direct competition with IL-21Journal of Biomedicine and Biotechnology 5
Expansion Contraction Memory
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T-bet
Blimp-1
Eomes
BCL-6
Figure 3: Expression of transcription factors in CD8 T cells is pos-
itively or negatively correlated with an inﬂammatory environment.
Prototypic CD8 T cell responses that are induced following acute
infection undergo three distinct phases: expansion, contraction,
and the establishment of memory. Each of these phases is associated
with shifts in the patterns of transcription factors expressed by
the responding cells. Expression of T-bet and Blimp-1 correlates
positively with inﬂammatory conditions, and their expression
is reduced as the infection becomes resolved, and the memory
pool develops. In contrast, Eomesodermin and Bcl-6 begin to be
expressed as the infection is brought under control and exhibit
highest expression in memory cells.
APC
CD4
IL-12
IL-2
IL-21
T-bet
Eomes
Blimp-1
BCL-6 ?
CD8
Figure 4: Regulation of transcription factors that impart CD8 T
cell fate and function by external signaling. Black arrows indicate
induction; red dots represent suppression. Blimp-1 and Bcl-6 are
mutually repressive in CD8 T cells. IL-21 induces both Blimp-1 and
Bcl-6 in B cells and is capable of inducing Blimp-1 in CD8 T cells.
Induction of Bcl-6 in response to IL-21 in CD8 T cells has yet to be
evaluated, as indicated by the dashed line with the question mark.
competent CD8 T cells in the chimeras [140–142]. Yi et al.
also made the intriguing observation that IL-21 treatment
of chronically infected CD4 deﬁcient mice can enhance the
virus-speciﬁc CD8 T cell response and reduce the viral load
[142], indicating that the levels of IL-21 may dictate both the
quality of the ensuing CD8 T cell response and the outcome
of the infection. Since CD4 T cells are a principle source
of IL-21, it is likely that this cytokine functions as a helper
factor that is vital for supporting CD8 T cell responses in
chronically infected hosts.
5.TranscriptionalRegulators inEffector,
Memory,andExhaustedCD8TCells
The transcriptional program in eﬀector, memory, and
exhausted CD8 T cells is both unique and overlapping.
Although the principal determinant of T cell diﬀerentiation
is the strength and duration of the antigenic signals that
the cells receive, a variety of other factors, including APC
interactions, availability of costimulation, the inﬂammatory
environment, and the presence of CD4 T cell help, act
together to set the transcriptional landscape at each phase
of the immune response. As outlined below, changes in
the levels of several factors, such as T-bet, Eomesodermin
(Eomes), Blimp-1, and Bcl-6, alter the transcriptional pro-
gram of the responding cell, which in turn imparts both the
functional capacity and fate of the pathogen-speciﬁc CD8 T
cell.
T-box transcription factor family members T-bet and
Eomes enforce the transcriptional program of eﬀector and
memory CD8 T cells. These transcription factors are related
and, in the CD8 T cell lineage, can partially compensate for
each other [144, 145]. T-bet deﬁciency in mice reduces but
does not completely ablate IFNγ production and cytolytic
activity in CD8 T cells [146], and T-bet deﬁcient mice are
still able to control LCMV-Armstrong [147]a n dListeria
monocytogenes [148] infections. Deletion of both T-bet
and Eomes in the CD8 T cell lineage eliminates IFNγ
production by the CD8 T cells and also dramatically shifts
the function of the cells to IL-17 production resulting in
massive inﬂammation and death after infection [147]. Thus,
T-bet and Eomes operate to deﬁne the speciﬁc functional
capabilities of CD8 T cells. The roles of T-bet and Eomes in
dictating the “CD8” eﬀector functions are further evidenced
bytheobservationthatbothofthesetranscriptionfactorsare
able to impart the capacity to produce IFNγ and granzyme B
in Th2 cells [149].
T-bet is induced by both IFNγ and IL-12 signaling [85,
150, 151] and is upregulated in response to inﬂammatory
signals (Figures 3 and 4). These signals, in conjunction with
the levels of T-bet expression, inﬂuence the generation of
eﬀector CD8 T cells following infection. T-bet is expressed at
higher levels in eﬀector T cells than in cells with a “memory
precursor” or memory phenotype (CD127hiKLRG-1lo)[ 83,
110]. In contrast, Eomes is induced later during the immune
response and is expressed at a higher level in memory CD8 T
cells compared to eﬀector cells [152, 153]( Figure 3). In the
absenceofT-bet,reducednumbersofpathogen-speciﬁcCD8
Tcellsaredetectedintheblood,spleen,andtissuesfollowing
infection with LCMV-Armstrong [110], Listeria monocyto-
genes [148], or Trypanosoma cruzi [154]. This reﬂects a
defect in the generation of eﬀector populations of CD8 T
cells, distinguished by the expression of high levels of KLRG-
1 and low levels of CD127 on their cell surface [83, 110]. The
pathogen-speciﬁc cells in T-bet deﬁcient mice instead adopt
a “central memory” phenotype (CD127hiKLRG-1loCD62Lhi)
[110, 148, 154] and elevated numbers of these CD8 T cell
are present in the lymph nodes [110]. Collectively, these
observations implicate T-bet as a factor necessary for the
generation of terminally diﬀerentiated eﬀector cells, while6 Journal of Biomedicine and Biotechnology
lower T-bet expression is permissive for memory CD8 T cell
generation.
In contrast to the role of T-bet in eﬀector CD8 T
cell development, Eomes is associated with memory CD8
T cell generation. T-bet deﬁcient mice fail to generate
CD127loKLRG-1hi eﬀector cells, but still develop protective
memory cells capable of producing IFNγ, and possess
cytotoxic activity by virtue of Eomes expression [144, 145,
147, 149, 152]. In vitro, IL-12 has been shown to reduce
E o m e sl e v e l s[ 153]( Figure 4), supporting a model in which
inﬂammation induces eﬀector CD8 T cell generation, and
resolution of the infection results in environmental signals
which favor Eomes upregulation and the emergence of
memory T cells (Figure 3).
In addition to regulation of T-bet and Eomes, IL-12 has
recentlybeenshowntoenhanceactivationofthemammalian
target of rapamycin (mTOR) after T cell activation. Inhibi-
tion of mTOR by the drug rapamycin mimics cell starvation
and results in cell cycle arrest and, at high doses, rapamycin
treatment is used to prevent immune-mediated rejection of
solid organ transplants. In light of its immunosuppressive
qualities, it is surprising that low doses of rapamycin have
been shown to improve generation of memory phenotype
CD8 T cells following infection or immunization [155,
156]. Inhibition of mTOR during either the priming or
contraction phase of the immune response enhanced the
number and fraction of responding T cells which exhibited
a memory type phenotype (CD127hiKLRG-1loCD62LhiBcl-
2hi)[ 155]. In vitro, treatment with rapamycin abrogated IL-
12-induced diﬀerentiation of na¨ ıve CD8 T cells, diminishing
both IFNγ production and T-bet expression. Instead, these
cells exhibited higher Eomes expression and were better
able to persist in vivo, expand upon a secondary challenge,
and protect against a tumor challenge, demonstrating their
enhanced memory potential [157]. Additionally, the drug
metformin has been shown to inﬂuence memory CD8
Tc e l ld i ﬀerentiation in a similar manner to rapamycin
treatment [156]. Metformin activates AMPK, an inhibitor of
mTOR, and may therefore be acting in a similar manner to
rapamycin treatment. In addition to the recently described
role in the regulation of T-bet and Eomes expression,
mTOR and AMPK may also function as a metabolic
switch to revert the anabolic metabolism of an eﬀector cell
(largely driven by glycolysis) to the catabolic metabolism
characteristic of na¨ ıve and resting memory cells (oxidative
phosphorylation) [158]. These metabolic shifts may act on
multiple pathways in the T cell to enforce the memory
phenotype.
Blimp-1 is a transcription factor that promotes diﬀeren-
t i a t i o ni nt h eC D 8Tc e l ll i n e a g ea sw e l la so t h e rc e l lt y p e s
[159]. Blimp-1 was ﬁrst identiﬁed in the B cell lineage, where
it drives the terminal diﬀerentiation of germinal center B
cells into plasma cells [160, 161]. Blimp-1 is expressed in
antigen experienced CD8 T cells, with higher expression in
eﬀector cells than memory T cells [162]. Deletion of Blimp-1
in mice leads to lymphoproliferative dysregulation, resulting
in death due to autoimmunity [162, 163], indicating a role
for Blimp-1 in restricting T cell responses. A system in which
Blimp-1 is deleted only from responding T cells by virtue of
granzyme B driven Cre expression has allowed the role of
Blimp-1 in T cell development and function to be elucidated.
Deletion of Blimp-1 in CD8 T cells responding to acute
LCMV-Armstrong [164] or inﬂuenza [165] infection led to
greatergenerationofvirus-speciﬁcCD8Tcells.Althoughthe
virus-speciﬁc response was larger with Blimp-1 deﬁciency,
these cells were less eﬀective at controlling infection and
had lower levels of eﬀector molecules such as granzyme B.
These Blimp-1 deﬁcient T cells could not fully diﬀerentiate
into eﬀector cells and instead formed an “altered” memory
pool of poorly functional cells, which were defective in their
capacity to proliferate in a secondary response [164, 165].
Shin et al. have demonstrated that during a chronic infection
Blimp-1expressionishighlyupregulated,correlatingwithits
high expression in eﬀector cells. In a chronic infection, CD8
T cells that lack Blimp-1 display a memory cell phenotype
and are partially protected from deletion despite high viral
loads in the conditional Blimp-1 knockout mice [166].
Intriguingly, Blimp-1 haploinsuﬃciency allowed accelerated
control of chronic LCMV clone-13 infection, indicating that
the level of Blimp-1 inﬂuences the functional capacity of the
T cells; without it T cells cannot execute eﬀector functions,
but if too highly expressed then the cells succumb to
exhaustion and are deleted. Thus the levels of Blimp-1 must
be tightly regulated to ensure a successful immune response
(Figure 3).
There are multiple repressors of Blimp-1 in the B cell
lineage; however, only one of these repressors is known to
be expressed in T cells, and that is B cell CLL/lymphoma
6 (Bcl-6) (Figure 4). Bcl-6 is involved in driving the home-
ostatic proliferation of CD8 T cells and the expansion and
maintenance of memory cells. Ordinarily, Bcl-6 is expressed
highly in central memory T cells, is moderately expressed
in eﬀector and eﬀector memory cells, and is not expressed
by na¨ ıve T cells [167]( Figure 3). Mice deﬁcient in Bcl-6
develop smaller responses to immunization compared to
wild type. By contrast, overexpression of Bcl-6 enhanced the
size of the antigen speciﬁc T cell response [167, 168], which
were primarily polarized to a central memory phenotype
and became distributed in the secondary lymphoid organs.
So it is plausible that Bcl-6 supports the diﬀerentiation
of central memory CD8 T cells. Bcl-6 also downregulates
Blimp-1 expression (Figure 4); so the enhanced numbers of
central memory cells generated in Bcl-6 transgenic mice may
be a result of lowered Blimp-1 expression. However, unlike
Blimp-1 deﬁcient T cells, eﬀector cells are still generated in
normal numbers in Bcl-6 transgenic mice. Thus both Bcl-
6 and Blimp-1 can be expressed in responding T cells, and
their relative levels may dictate the function and fate of the T
cell.
6. FutureDirections
Many advances have been made in our understanding
of CD8 T cell diﬀerentiation and how these responses
contribute to infection control; nevertheless, more progressJournal of Biomedicine and Biotechnology 7
is needed. Although early activation events and the APC-
T cell interaction are an essential ﬁrst step in priming
CD8 T cell responses, how exactly these events fully shape
the development of remarkably heterogeneous responses
remains unclear. Elucidating whether or not polarization
of the responding CD8 T cell and potential asymmetric
division of the activated na¨ ıve CD8 T cell truly dictates the
subsequent diﬀerentiation of the daughter cells is clearly
of interest [25, 169]. Although development of CD8 T cell
exhaustion is increasingly well described, we still do not
fully understand all of the factors that drive these inferior
responses, and importantly, we need to determine better
strategies for reversing or circumventing the exhausted state.
This is necessary if curative immune-based approaches are
to be developed for persistent infections, and it will also be
essential to devise methods that promote control of these
infections while avoiding widespread immunopathology.
Our understanding of the requirements for CD4 T cell
help for CD8 T cell responses has improved in recent
years and the importance of IL-21 in this process has
been highlighted. Additional studies will be required to
better understand exactly how IL-21 functions to promote
CD8 T cell responses and what the key diﬀerences are
between CD8 T cells which do and do not receive IL-21
signals.
Given the pivotal importance of transcriptional regula-
tors in dictating CD8 T cell fate, a better understanding
of the signals that induce expression of these factors,
their exact function, and how these factors integrate their
transcriptional program is warranted. T-bet and Blimp-1
appear to operate in a “rheostat” mechanism, where little
to no expression depreciates eﬀector capabilities, while too
high expression results in terminally diﬀerentiated cells and
a loss of proliferative capacity. We will need to know not
only the appropriate levels of these transcription factors that
elicit long lived central and eﬀector memory populations,
but also what signals induce expression of these molecules,
and whether they can control the expression of one another.
Expression of the transcription factors Eomes and Bcl-6 are
also associated with memory T cell generation; however,
little is known about how these molecules are induced or
regulated in the T cell lineage. Thus, it will be interesting
to discover what nonoverlapping functions these two tran-
scription factors have with T-bet and Blimp-1, which allow
the high proliferative potential and maintenance of eﬀector
functions in memory CD8 T cells. Given the multitude of
gaps in our understanding of CD8 T cell biology it is likely
that this area of research will continue to be exciting and
surprising.
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